Rein Therapeutics (NASDAQ:RNTX – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research note issued on Wednesday, Benzinga reports.
Separately, Weiss Ratings lowered Rein Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, August 21st. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Rein Therapeutics currently has an average rating of “Hold” and a consensus price target of $6.00.
Read Our Latest Stock Report on Rein Therapeutics
Rein Therapeutics Stock Down 10.9%
Shares of NASDAQ:RNTX opened at $0.36 on Wednesday. The firm has a 50 day moving average of $0.69 and a 200 day moving average of $1.00. The company has a market capitalization of $30.75 million, a price-to-earnings ratio of -0.23 and a beta of 1.47. Rein Therapeutics has a 52 week low of $0.28 and a 52 week high of $2.10.
Rein Therapeutics (NASDAQ:RNTX – Get Free Report) last announced its earnings results on Monday, November 16th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.04. On average, sell-side analysts expect that Rein Therapeutics will post -0.47 EPS for the current year.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of RNTX. Velan Capital Investment Management LP purchased a new stake in shares of Rein Therapeutics during the second quarter valued at $1,768,000. Texas Capital Bank Wealth Management Services Inc raised its stake in Rein Therapeutics by 19.9% in the 3rd quarter. Texas Capital Bank Wealth Management Services Inc now owns 360,758 shares of the company’s stock worth $290,000 after acquiring an additional 60,000 shares during the last quarter. Sequoia Financial Advisors LLC purchased a new position in Rein Therapeutics in the 2nd quarter worth $260,000. Rock Creek Group LLC lifted its position in Rein Therapeutics by 40.0% during the 3rd quarter. Rock Creek Group LLC now owns 175,000 shares of the company’s stock worth $141,000 after acquiring an additional 50,000 shares during the period. Finally, Marshall Wace LLP acquired a new stake in Rein Therapeutics during the 3rd quarter worth about $127,000. Institutional investors and hedge funds own 90.89% of the company’s stock.
About Rein Therapeutics
Rein Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for serious pulmonary and fibrotic diseases. Its research focuses on therapies intended to address disease processes involved in lung injury and fibrosis. The company’s pipeline includes LTI-03, an investigational candidate being developed for idiopathic pulmonary fibrosis, and LTI-01, a candidate studied for loculated pleural effusions. These programs are investigational; they are not approved treatments.
Further Reading
- Five stocks we like better than Rein Therapeutics
- 3 Stocks Flashing Buy Signals With Historical Win Rates Above 85% After the Sell-Off
- Disney Has the Magic Touch: Dividend Growth and Buybacks Could Fuel a Breakout
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
Receive News & Ratings for Rein Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rein Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
